Drug Detail:Zetia (Ezetimibe [ ez-et-i-mibe ])
Drug Class: Cholesterol absorption inhibitors
Highlights of Prescribing Information
ZETIA® (ezetimibe) tablets, for oral use
Initial U.S. Approval: 2002
Recent Major Changes
Indications and Usage (1) | 7/2023 |
Dosage and Administration (2) | 7/2023 |
Contraindications (4) | 7/2023 |
Warnings and Precautions (5.1, 5.2, 5.3) | 7/2023 |
Indications and Usage for Zetia
ZETIA is indicated (1):
- In combination with a statin, or alone when additional low density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).
- In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH.
- In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia.
- In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH).
- As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia.
When ZETIA is used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use (1).
Zetia Dosage and Administration
- 10-mg orally once daily, with or without food (2)
- Administer ZETIA either ≥2 hours before or ≥4 hours after administration of a bile acid sequestrant. (2)
- Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ZETIA. (2)
Dosage Forms and Strengths
- Tablets: 10 mg (3)
Contraindications
- Hypersensitivity to ezetimibe or any excipient of ZETIA. (4)
- When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. Refer to the Prescribing Information of these products for a list of their contraindications. (4)
Warnings and Precautions
- Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies: Refer to the Prescribing Information of these products for a description of their risks including, but not limited to, the warnings and precautions. (5.1)
- Liver Enzyme Abnormalities and Monitoring: Increases in serum transaminases have been reported with use of ZETIA. Perform liver enzyme testing as clinically indicated and consider withdrawal of ZETIA if increases in ALT or AST ≥3 × ULN persist. (5.2)
- Skeletal Muscle Effects (e.g., Myopathy and Rhabdomyolysis): ZETIA may cause myopathy and rhabdomyolysis. In post-marketing reports, most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk of rhabdomyolysis, such as fibrates. If myopathy is suspected, discontinue ZETIA and other concomitant medications, as appropriate. (5.3)
Adverse Reactions/Side Effects
- Common adverse reactions in clinical trials:
- ZETIA administered alone (incidence ≥2% and greater than placebo): upper respiratory tract infection, diarrhea, arthralgia, sinusitis, pain in extremity, fatigue, and influenza (6.1)
- ZETIA coadministered with a statin (incidence ≥2% and greater than statin alone): nasopharyngitis, myalgia, upper respiratory tract infection, arthralgia, diarrhea, back pain, influenza, pain in extremity, and fatigue (6.1)
To report SUSPECTED ADVERSE REACTIONS, contact Organon LLC, a subsidiary of Organon & Co., at 1-844-674-3200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Drug Interactions
- Cyclosporine: Combination increases exposure of ZETIA and cyclosporine. Cyclosporine concentrations should be monitored in patients taking ZETIA concomitantly. (7)
- Fibrates: Coadministration of ZETIA with fibrates other than fenofibrate is not recommended until use in patients is adequately studied. If cholelithiasis is suspected in a patient receiving ZETIA and fenofibrate, gallbladder studies are indicated, and alternative lipid-lowering therapy should be considered. (7)
- Bile Acid Sequestrants: Cholestyramine combination decreases exposure of ZETIA. (7)
See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.
Revised: 7/2023
Related/similar drugs
atorvastatin, rosuvastatin, simvastatin, Lipitor, ezetimibe, Crestor, lovastatinFull Prescribing Information
1. Indications and Usage for Zetia
ZETIA® is indicated:
- In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).
- In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH.
- In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia.
- In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH).
- As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia.
When ZETIA is used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use.
2. Zetia Dosage and Administration
- The recommended dose of ZETIA is 10 mg orally once daily, administered with or without food.
- If as dose is missed, take the missed dose as soon as possible. Do not double the next dose.
- Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ZETIA.
- In patients taking a bile acid sequestrant, administer ZETIA at least 2 hours before or 4 hours after the bile acid sequestrant [see Drug Interactions (7)].
3. Dosage Forms and Strengths
Tablets: 10-mg white to off-white, capsule-shaped, and debossed with "414" on one side.
4. Contraindications
ZETIA is contraindicated in patients with a known hypersensitivity to ezetimibe or any of the excipients in ZETIA. Hypersensitivity reactions including anaphylaxis, angioedema, rash, and urticaria have been reported [see Adverse Reactions (6.2)].
When used in combination with a statin, fenofibrate, or other LDL-C lowering therapy, ZETIA is contraindicated in patients for whom a statin, fenofibrate, or other LDL-C lowering therapy are contraindicated. Refer to the Prescribing Information of these products for a list of their contraindications [see Warnings and Precautions (5.1)].
5. Warnings and Precautions
5.1 Risks Associated with Combination Treatment with a Statin, Fenofibrate, or Other LDL-C Lowering Therapies
If ZETIA is administered with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for a description of their risks including, but not limited to, the warnings and precautions [see Contraindications (4)].
5.2 Liver Enzymes
Increases in serum transaminases have been reported with use of ZETIA [see Adverse Reactions (6.1)]. In controlled clinical combination studies of ZETIA initiated concurrently with a statin, the incidence of consecutive elevations (≥3 × ULN) in hepatic transaminase levels was 1.3% for patients treated with ZETIA administered with statins and 0.4% for patients treated with statins alone. Perform liver enzyme testing as clinically indicated and consider withdrawal of ZETIA if increases in ALT or AST ≥3 × ULN persist.
5.3 Myopathy/Rhabdomyolysis
ZETIA may cause myopathy [muscle pain, tenderness, or weakness associated with elevated creatine kinase (CK)] and rhabdomyolysis [see Adverse Reactions (6.1)]. In post-marketing reports, most patients who developed rhabdomyolysis were taking a statin or other agents known to be associated with an increased risk of rhabdomyolysis, such as fibrates. If myopathy is suspected, discontinue ZETIA and other concomitant medications, as appropriate.
6. Adverse Reactions/Side Effects
The following serious adverse reactions are discussed in greater detail in other sections of the label:
- Liver enzyme abnormalities [see Warnings and Precautions (5.2)]
- Rhabdomyolysis and myopathy [see Warnings and Precautions (5.3)]
6.1 Clinical Trials Experience
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in clinical practice.
Monotherapy
In 10 double-blind, placebo-controlled clinical trials, 2,396 patients with primary hyperlipidemia (age range 9 to 86 years; 50% female, 90% White, 5% Black or African American, 2% Asian, 3% other races; 3% identified as Hispanic or Latino ethnicity) and elevated LDL-C were treated with ZETIA 10 mg daily for a median treatment duration of 12 weeks (range 0 to 39 weeks).
Adverse reactions reported in ≥2% of patients treated with ZETIA and at an incidence greater than placebo in placebo-controlled studies of ZETIA are shown in Table 1.
Adverse Reaction | Placebo (%) n = 1,159 | ZETIA 10 mg (%) n = 2,396 |
Upper respiratory tract infection | 2.5 | 4.3 |
Diarrhea | 3.7 | 4.1 |
Arthralgia | 2.2 | 3.0 |
Sinusitis | 2.2 | 2.8 |
Pain in extremity | 2.5 | 2.7 |
Fatigue | 1.5 | 2.4 |
Influenza | 1.5 | 2.0 |
Combination with a Statin
In 28 double-blind, controlled (placebo or active-controlled) clinical trials, 11,308 patients with primary hyperlipidemia (age range 10 to 93 years, 48% female, 85% White, 7% Black or African American, 3% Asian, 5% other races; 4% identified as Hispanic or Latino ethnicity) and elevated LDL-C were treated with ZETIA 10 mg/day concurrently with or added to on-going statin therapy for a median treatment duration of 8 weeks (range 0 to 112 weeks).
The incidence of consecutive increased transaminases (≥3 × ULN) was higher in patients receiving ZETIA administered with statins (1.3%) than in patients treated with statins alone (0.4%).
Adverse reactions reported in ≥2% of patients treated with ZETIA + statin and at an incidence greater than statin are shown in Table 2.
|
||
Adverse Reaction | All Statins*
(%) n = 9,361 | ZETIA + All Statins*
(%) n = 11,308 |
Nasopharyngitis | 3.3 | 3.7 |
Myalgia | 2.7 | 3.2 |
Upper respiratory tract infection | 2.8 | 2.9 |
Arthralgia | 2.4 | 2.6 |
Diarrhea | 2.2 | 2.5 |
Back pain | 2.3 | 2.4 |
Influenza | 2.1 | 2.2 |
Pain in extremity | 1.9 | 2.1 |
Fatigue | 1.6 | 2.0 |
6.2 Post-Marketing Experience
Because the reactions below are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following additional adverse reactions have been identified during post-approval use of ZETIA:
Blood Disorders: thrombocytopenia
Gastrointestinal Disorders: abdominal pain; pancreatitis; nausea
Hepatobiliary Disorders: elevations in liver transaminases; hepatitis; cholelithiasis; cholecystitis
Immune System Disorders: Hypersensitivity reactions including: anaphylaxis, angioedema, rash, and urticaria
Musculoskeletal Disorders: elevated creatine phosphokinase; myopathy/rhabdomyolysis
Nervous System Disorders: dizziness; paresthesia; depression; headache
Skin and Subcutaneous Tissue Disorders: erythema multiforme
7. Drug Interactions
Table 3 includes a list of drugs with clinically important drug interactions when administered concomitantly with ZETIA and instructions for preventing or managing them.
Cyclosporine | |
---|---|
Clinical Impact: | Concomitant use of ZETIA and cyclosporine increases ezetimibe and cyclosporine concentrations. The degree of increase in ezetimibe exposure may be greater in patients with severe renal insufficiency [see Clinical Pharmacology (12.3)]. |
Intervention: | Monitor cyclosporine concentrations in patients receiving ZETIA and cyclosporine. In patients treated with cyclosporine, weigh the potential effects of the increased exposure to ezetimibe from concomitant use against the benefits of alterations in lipid levels provided by ZETIA. |
Fibrates | |
Clinical Impact: | Both fenofibrate and ezetimibe may increase cholesterol excretion into the bile, leading to cholelithiasis. Co-administration of ZETIA with fibrates other than fenofibrate is not recommended [see Adverse Reactions (6.1)]. |
Intervention: | If cholelithiasis is suspected in a patient receiving ZETIA and fenofibrate, gallbladder studies are indicated, and alternative lipid-lowering therapy should be considered. |
Bile Acid Sequestrants | |
Clinical Impact: | Concomitant cholestyramine administration decreased the mean exposure of total ezetimibe. This may result in a reduction of efficacy [see Clinical Pharmacology (12.3)]. |
Intervention: | In patients taking a bile acid sequestrant, administer ZETIA at least 2 hours before or 4 hours after the bile acid sequestrant [see Dosage and Administration (2)]. |
8. Use In Specific Populations
8.1 Pregnancy
Risk Summary
There are insufficient data on ezetimibe use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. In animal reproduction studies, no adverse developmental effects were observed in pregnant rats and rabbits orally administered ezetimibe during the period of organogenesis at doses that resulted in up to 10 and 150 times, respectively, the human exposure at the MRHD, based on AUC (see Data). ZETIA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. When ZETIA is administered with a statin, refer to the Prescribing Information for the statin.
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.
8.2 Lactation
Risk Summary
There is no information about the presence of ezetimibe in human milk. Ezetimibe is present in rat milk (see Data). When a drug is present in animal milk, it is likely that the drug will be present in human milk. There is no information about the effects of ezetimibe on the breastfed infant or the effects of ezetimibe on milk production. ZETIA should not be used in nursing mothers unless the potential benefit justifies the potential risk to the infant.
8.4 Pediatric Use
The safety and effectiveness of ZETIA in combination with a statin as an adjunct to diet to reduce LDL-C have been established in pediatric patients 10 years of age and older with HeFH. Use of ZETIA for this indication is based on a double-blind, placebo-controlled clinical trial in 248 pediatric patients (142 males and 106 postmenarchal females) 10 years of age and older with HeFH [see Clinical Studies (14)]. In this limited controlled trial, there was no significant effect on growth or sexual maturation in the adolescent males or females, or on menstrual cycle length in females.
The safety and effectiveness of ZETIA in combination with a statin, and other LDL-C lowering therapies, to reduce LDL-C have been established in pediatric patients 10 years of age and older with HoFH. Use of ZETIA for this indication is based on a 12-week double-blind, placebo-controlled clinical trial followed by an uncontrolled extension period in 7 pediatric patients 11 years of age and older with HoFH [see Clinical Studies (14)].
The safety and effectiveness of ZETIA as an adjunct to diet for the reduction of elevated sitosterol and campesterol levels have been established in adults and pediatric patients 9 years of age and older with homozygous familial sitosterolemia. Use of ZETIA for this indication is based on an 8-week double-blind, placebo-controlled clinical trial in 4 patients 9 years of age and older with homozygous sitosterolemia with elevated plasma sitosterol levels (>5 mg/dL) [see Clinical Studies (14)].
The safety and effectiveness of ZETIA have not been established in pediatric patients younger than 10 years of age with HeFH or HoFH, in pediatric patients younger than 9 years of age with homozygous familial sitosterolemia, or in pediatric patients with other types of hyperlipidemia.
8.5 Geriatric Use
Of the 2,396 patients who received ZETIA in clinical trials, 669 (28%) were 65 years of age and older, and 111 (5%) were 75 years of age and older. Of the 11,308 patients who received ZETIA in combination with a statin in clinical trials, 3587 (32%) were 65 years of age and older, and 924 (8%) were 75 years of age and older [see Clinical Studies (14)]. No overall differences in safety or effectiveness of ZETIA have been observed between patients 65 years of age and older and younger patients. No clinically meaningful differences in the pharmacokinetics of ezetimibe were observed in geriatric patients compared to younger adult patients [see Clinical Pharmacology (12.3)].
10. Overdosage
In the event of overdose, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.
11. Zetia Description
ZETIA (ezetimibe) is a dietary cholesterol absorption inhibitor. The chemical name of ezetimibe is 1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone. The empirical formula is C24H21F2NO3. Its molecular weight is 409.4 and its structural formula is:
Ezetimibe is a white, crystalline powder that is freely to very soluble in ethanol, methanol, and acetone and practically insoluble in water. Ezetimibe has a melting point of about 163°C and is stable at ambient temperature. ZETIA is available as a tablet for oral use containing 10 mg of ezetimibe and the following inactive ingredients: croscarmellose sodium NF, lactose monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, povidone USP, and sodium lauryl sulfate NF.
12. Zetia - Clinical Pharmacology
12.1 Mechanism of Action
Ezetimibe reduces blood cholesterol by inhibiting the absorption of cholesterol by the small intestine.
The molecular target of ezetimibe has been shown to be the sterol transporter, Niemann-Pick C1-Like 1 (NPC1L1), which is involved in the intestinal uptake of cholesterol and phytosterols. Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver. This causes a reduction of hepatic cholesterol stores and an increase in LDL receptors, resulting in clearance of cholesterol from the blood.
12.2 Pharmacodynamics
ZETIA reduces total cholesterol (total-C), LDL-C, apolipoprotein (Apo) B, and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with hyperlipidemia.
In a 2-week clinical trial in 18 hypercholesterolemic patients, ZETIA inhibited intestinal cholesterol absorption by 54%, compared with placebo. ZETIA had no clinically meaningful effect on the plasma concentrations of the fat-soluble vitamins A, D, and E (in a trial of 113 patients) and did not impair adrenocortical steroid hormone production (in a trial of 118 patients).
12.3 Pharmacokinetics
Gender
In a multiple-dose trial with ezetimibe given 10 mg once daily for 10 days, plasma concentrations for total ezetimibe were slightly higher (<20%) in females than in males.
Race
Based on a meta-analysis of multiple-dose pharmacokinetic studies, there were no pharmacokinetic differences between Black and White subjects. Studies in Asian subjects indicated that the pharmacokinetics of ezetimibe were similar to those seen in White subjects.
Renal Impairment
After a single 10-mg dose of ezetimibe in patients with severe renal disease (n=8; mean CrCl ≤30 mL/min/1.73 m2), the mean AUC values for total ezetimibe, ezetimibe-glucuronide, and ezetimibe were increased approximately 1.5-fold, compared to healthy subjects (n=9).
Hepatic Impairment
After a single 10-mg dose of ezetimibe, the mean AUC for total ezetimibe was increased approximately 1.7-fold in patients with mild hepatic impairment (Child-Pugh score 5 to 6), compared to healthy subjects. The mean AUC values for total ezetimibe and ezetimibe were increased approximately 3- to 4-fold and 5- to 6-fold, respectively, in patients with moderate (Child-Pugh score 7 to 9) or severe hepatic impairment (Child-Pugh score 10 to 15). In a 14-day, multiple-dose trial (10 mg daily) in patients with moderate hepatic impairment, the mean AUC values for total ezetimibe and ezetimibe were increased approximately 4-fold on Day 1 and Day 14 compared to healthy subjects [see Use in Specific Populations (8.7)].
Drug Interactions
ZETIA had no significant effect on a series of probe drugs (caffeine, dextromethorphan, tolbutamide, and IV midazolam) known to be metabolized by cytochrome P450 (1A2, 2D6, 2C8/9 and 3A4) in a “cocktail” trial of twelve healthy adult males. This indicates that ezetimibe is neither an inhibitor nor an inducer of these cytochrome P450 isozymes, and it is unlikely that ezetimibe will affect the metabolism of drugs that are metabolized by these enzymes.
Coadministered Drug and Dosing Regimen | Total Ezetimibe* | |
---|---|---|
Change in AUC | Change in Cmax | |
|
||
Cyclosporine-stable dose required (75-150 mg BID)†, ‡ | ↑240% | ↑290% |
Fenofibrate, 200 mg QD, 14 days‡ | ↑48% | ↑64% |
Gemfibrozil, 600 mg BID, 7 days‡ | ↑64% | ↑91% |
Cholestyramine, 4 g BID, 14 days‡ | ↓55% | ↓4% |
Aluminum & magnesium hydroxide combination antacid, single dose§ | ↓4% | ↓30% |
Cimetidine, 400 mg BID, 7 days | ↑6% | ↑22% |
Glipizide, 10 mg, single dose | ↑4% | ↓8% |
Statins | ||
Lovastatin 20 mg QD, 7 days | ↑9% | ↑3% |
Pravastatin 20 mg QD, 14 days | ↑7% | ↑23% |
Atorvastatin 10 mg QD, 14 days | ↓2% | ↑12% |
Rosuvastatin 10 mg QD, 14 days | ↑13% | ↑18% |
Fluvastatin 20 mg QD, 14 days | ↓19% | ↑7% |
Coadministered Drug and its Dosage Regimen | Ezetimibe Dosage Regimen | Change in AUC of Coadministered Drug | Change in Cmax
of Coadministered Drug |
---|---|---|---|
|
|||
Warfarin, 25-mg single dose on Day 7 | 10 mg QD, 11 days | ↓2% (R-warfarin) ↓4% (S-warfarin) | ↑3% (R-warfarin) ↑1% (S-warfarin) |
Digoxin, 0.5-mg single dose | 10 mg QD, 8 days | ↑2% | ↓7% |
Gemfibrozil, 600 mg BID, 7 days* | 10 mg QD, 7 days | ↓1% | ↓11% |
Ethinyl estradiol & Levonorgestrel, QD, 21 days | 10 mg QD, days 8-14 of 21d oral contraceptive cycle | Ethinyl estradiol 0% Levonorgestrel 0% | Ethinyl estradiol ↓9% Levonorgestrel ↓5% |
Glipizide, 10 mg on Days 1 and 9 | 10 mg QD, days 2-9 | ↓3% | ↓5% |
Fenofibrate, 200 mg QD, 14 days* | 10 mg QD, 14 days | ↑11% | ↑7% |
Cyclosporine, 100-mg single dose Day 7* | 20 mg QD, 8 days | ↑15% | ↑10% |
Statins | |||
Lovastatin 20 mg QD, 7 days | 10 mg QD, 7 days | ↑19% | ↑3% |
Pravastatin 20 mg QD, 14 days | 10 mg QD, 14 days | ↓20% | ↓24% |
Atorvastatin 10 mg QD, 14 days | 10 mg QD, 14 days | ↓4% | ↑7% |
Rosuvastatin 10 mg QD, 14 days | 10 mg QD, 14 days | ↑19% | ↑17% |
Fluvastatin 20 mg QD, 14 days | 10 mg QD, 14 days | ↓39% | ↓27% |
13. Nonclinical Toxicology
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
A 104-week dietary carcinogenicity study with ezetimibe was conducted in rats at doses up to 1,500 mg/kg/day (males) and 500 mg/kg/day (females) (~20 × the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). A 104-week dietary carcinogenicity study with ezetimibe was also conducted in mice at doses up to 500 mg/kg/day (>150 × the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe). There were no statistically significant increases in tumor incidences in drug-treated rats or mice.
No evidence of mutagenicity was observed in vitro in a microbial mutagenicity (Ames) test with Salmonella typhimurium and Escherichia coli with or without metabolic activation. No evidence of clastogenicity was observed in vitro in a chromosomal aberration assay in human peripheral blood lymphocytes with or without metabolic activation. In addition, there was no evidence of genotoxicity in the in vivo mouse micronucleus test.
In oral (gavage) fertility studies of ezetimibe conducted in rats, there was no evidence of reproductive toxicity at doses up to 1,000 mg/kg/day in male or female rats (~7 × the human exposure at 10 mg daily based on AUC0-24hr for total ezetimibe).
14. Clinical Studies
Primary Hyperlipidemia in Adults
ZETIA reduces total-C, LDL-C, Apo B, and non-HDL-C in patients with hyperlipidemia. Maximal to near maximal response is generally achieved within 2 weeks and maintained during chronic therapy.
Monotherapy
In two multicenter, double-blind, placebo-controlled, 12-week trials in 1719 patients (age range 18 to 86 years, 52% females; 91% White, 5% Black or African American, 1% Asian, 3% other races mostly identified as Hispanic or Latino ethnicity) with primary hyperlipidemia, ZETIA significantly lowered total-C, LDL-C, Apo B, and non-HDL-C compared to placebo (see Table 6). Reduction in LDL-C was consistent across age, sex, and baseline LDL-C.
Treatment Group | N | Total-C | LDL-C | Apo B | Non-HDL-C | |
---|---|---|---|---|---|---|
|
||||||
Trial 1† | Placebo | 205 | +1 | +1 | -1 | +1 |
Ezetimibe | 622 | -12 | -18 | -15 | -16 | |
Trial 2† | Placebo | 226 | +1 | +1 | -1 | +2 |
Ezetimibe | 666 | -12 | -18 | -16 | -16 | |
Pooled Data† (Trials 1 & 2) | Placebo | 431 | 0 | +1 | -2 | +1 |
Ezetimibe | 1288 | -13 | -18 | -16 | -16 |
Combination with Statins: ZETIA Added to On-going Statin Therapy
In a multicenter, double-blind, placebo-controlled, 8-week trial, 769 patients (age range 22 to 85 years, 42% females; 90% White, 6% Black or African American, 1% Asian, 3% other races; and 2% identified as Hispanic or Latino ethnicity) with primary hyperlipidemia, known coronary heart disease or multiple cardiovascular risk factors who were already receiving statin monotherapy but who had not met their NCEP ATP II target LDL-C goal, were randomized to receive either ZETIA or placebo in addition to their on-going statin.
ZETIA, added to on-going statin therapy, significantly lowered total-C, LDL-C, Apo B, and non-HDL-C compared with a statin administered alone (see Table 7). LDL-C reductions induced by ZETIA were generally consistent across all statins.
Treatment (Daily Dose) | N | Total-C | LDL-C | Apo B | Non-HDL-C |
---|---|---|---|---|---|
|
|||||
On-going Statin + Placebo‡ | 390 | -2 | -4 | -3 | -3 |
On-going Statin + ZETIA‡ | 379 | -17 | -25 | -19 | -23 |
Combination with Statins: ZETIA Initiated Concurrently with a Statin
In four multicenter, double-blind, placebo-controlled, 12-week trials, in 2,382 patients (age range 18 to 87 years, 57% female; 88% White, 5% Black or African American, 2% Asian, 5% other races mostly identified as Hispanic or Latino) with hyperlipidemia, ZETIA or placebo was administered alone or with various doses of atorvastatin, simvastatin, pravastatin, or lovastatin.
When all patients receiving ZETIA with a statin were compared to all those receiving the corresponding statin alone, ZETIA significantly lowered total-C, LDL-C, Apo B, and non-HDL-C compared to the statin administered alone. LDL-C reductions induced by ZETIA were generally consistent across all statins. (See footnote †, Tables 8 to 11.)
Treatment (Daily Dose) | N | Total-C | LDL-C | Apo B | Non-HDL-C |
---|---|---|---|---|---|
|
|||||
Placebo | 60 | +4 | +4 | +3 | +4 |
ZETIA | 65 | -14 | -20 | -15 | -18 |
Atorvastatin 10 mg | 60 | -26 | -37 | -28 | -34 |
ZETIA + Atorvastatin 10 mg | 65 | -38 | -53 | -43 | -49 |
Atorvastatin 20 mg | 60 | -30 | -42 | -34 | -39 |
ZETIA + Atorvastatin 20 mg | 62 | -39 | -54 | -44 | -50 |
Atorvastatin 40 mg | 66 | -32 | -45 | -37 | -41 |
ZETIA + Atorvastatin 40 mg | 65 | -42 | -56 | -45 | -52 |
Atorvastatin 80 mg | 62 | -40 | -54 | -46 | -51 |
ZETIA + Atorvastatin 80 mg | 63 | -46 | -61 | -50 | -58 |
Pooled data (All Atorvastatin Doses)† | 248 | -32 | -44 | -36 | -41 |
Pooled data (All ZETIA + Atorvastatin Doses)† | 255 | -41 | -56 | -45 | -52 |
Treatment (Daily Dose) | N | Total-C | LDL-C | Apo B | Non-HDL-C |
---|---|---|---|---|---|
|
|||||
Placebo | 70 | -1 | -1 | 0 | -1 |
ZETIA | 61 | -13 | -19 | -14 | -17 |
Simvastatin 10 mg | 70 | -18 | -27 | -21 | -25 |
ZETIA + Simvastatin 10 mg | 67 | -32 | -46 | -35 | -42 |
Simvastatin 20 mg | 61 | -26 | -36 | -29 | -33 |
ZETIA + Simvastatin 20 mg | 69 | -33 | -46 | -36 | -42 |
Simvastatin 40 mg | 65 | -27 | -38 | -32 | -35 |
ZETIA + Simvastatin 40 mg | 73 | -40 | -56 | -45 | -51 |
Simvastatin 80 mg | 67 | -32 | -45 | -37 | -41 |
ZETIA + Simvastatin 80 mg | 65 | -41 | -58 | -47 | -53 |
Pooled data (All Simvastatin Doses)† | 263 | -26 | -36 | -30 | -34 |
Pooled data (All ZETIA + Simvastatin Doses)† | 274 | -37 | -51 | -41 | -47 |
Treatment (Daily Dose) | N | Total-C | LDL-C | Apo B | Non-HDL-C |
---|---|---|---|---|---|
|
|||||
Placebo | 65 | 0 | -1 | -2 | 0 |
ZETIA | 64 | -13 | -20 | -15 | -17 |
Pravastatin 10 mg | 66 | -15 | -21 | -16 | -20 |
ZETIA + Pravastatin 10 mg | 71 | -24 | -34 | -27 | -32 |
Pravastatin 20 mg | 69 | -15 | -23 | -18 | -20 |
ZETIA + Pravastatin 20 mg | 66 | -27 | -40 | -31 | -36 |
Pravastatin 40 mg | 70 | -22 | -31 | -26 | -28 |
ZETIA + Pravastatin 40 mg | 67 | -30 | -42 | -32 | -39 |
Pooled data (All Pravastatin Doses)† | 205 | -17 | -25 | -20 | -23 |
Pooled data (All ZETIA + Pravastatin Doses)† | 204 | -27 | -39 | -30 | -36 |
Treatment (Daily Dose) | N | Total-C | LDL-C | Apo B | Non-HDL-C |
---|---|---|---|---|---|
|
|||||
Placebo | 64 | +1 | 0 | +1 | +1 |
ZETIA | 72 | -13 | -19 | -14 | -16 |
Lovastatin 10 mg | 73 | -15 | -20 | -17 | -19 |
ZETIA + Lovastatin 10 mg | 65 | -24 | -34 | -27 | -31 |
Lovastatin 20 mg | 74 | -19 | -26 | -21 | -24 |
ZETIA + Lovastatin 20 mg | 62 | -29 | -41 | -34 | -39 |
Lovastatin 40 mg | 73 | -21 | -30 | -25 | -27 |
ZETIA + Lovastatin 40 mg | 65 | -33 | -46 | -38 | -43 |
Pooled data (All Lovastatin Doses)† | 220 | -18 | -25 | -21 | -23 |
Pooled data (All ZETIA + Lovastatin Doses)† | 192 | -29 | -40 | -33 | -38 |
Combination with Fenofibrate
In a multicenter, double-blind, placebo-controlled, clinical trial in patients with mixed hyperlipidemia, 625 patients (age range 20 to 76 years, 44% female; 79% White, 1% Black or African American, 20% other races; and 11% identified as Hispanic or Latino ethnicity) were treated for up to 12 weeks and 576 for up to an additional 48 weeks. Patients were randomized to receive placebo, ZETIA alone, 160 mg fenofibrate alone, or ZETIA and 160 mg fenofibrate in the 12-week trial. After completing the 12-week trial, eligible patients were assigned to ZETIA coadministered with fenofibrate or fenofibrate monotherapy for an additional 48 weeks.
ZETIA coadministered with fenofibrate significantly lowered total-C, LDL-C, Apo B, and non-HDL-C compared to fenofibrate administered alone (see Table 12).
Treatment (Daily Dose) | N | Total-C | LDL-C | Apo B | Non-HDL-C |
---|---|---|---|---|---|
|
|||||
Placebo | 63 | 0 | 0 | -1 | 0 |
ZETIA | 185 | -12 | -13 | -11 | -15 |
Fenofibrate 160 mg | 188 | -11 | -6 | -15 | -16 |
ZETIA + Fenofibrate 160 mg | 183 | -22 | -20 | -26 | -30 |
The changes in lipid endpoints after an additional 48 weeks of treatment with ZETIA coadministered with fenofibrate or with fenofibrate alone were consistent with the 12-week data displayed above.
HeFH in Pediatric Patients
The effects of ZETIA coadministered with simvastatin (n=126) compared to simvastatin monotherapy (n=122) have been evaluated in males and females with HeFH. In a multicenter, double-blind, controlled trial followed by an open-label phase, 142 males and 106 postmenarchal females, 10 to 17 years of age (mean age 14.2 years, 43% females, 82% White, 4% Asian, 2% Black or African American, 13% multi-racial; 14% identified as Hispanic or Latino ethnicity) with HeFH were randomized to receive either ZETIA coadministered with simvastatin or simvastatin monotherapy. Inclusion in the trial required 1) a baseline LDL-C level between 160 and 400 mg/dL and 2) a medical history and clinical presentation consistent with HeFH. The mean baseline LDL-C value was 225 mg/dL (range: 161 to 351 mg/dL) in the ZETIA coadministered with simvastatin group compared to 219 mg/dL (range: 149 to 336 mg/dL) in the simvastatin monotherapy group. The patients received coadministered ZETIA and simvastatin (10 mg, 20 mg, or 40 mg) or simvastatin monotherapy (10 mg, 20 mg, or 40 mg) for 6 weeks, coadministered ZETIA and 40-mg simvastatin or 40-mg simvastatin monotherapy for the next 27 weeks, and open-label coadministered ZETIA and simvastatin (10 mg, 20 mg, or 40 mg) for 20 weeks thereafter.
The results of the trial at Week 6 are summarized in Table 13. Results at Week 33 were consistent with those at Week 6.
Total-C | LDL-C | Apo B | Non-HDL-C | |
---|---|---|---|---|
Mean percent difference between treatment groups | -12% | -15% | -12% | -14% |
95% Confidence Interval | (-15%, -9%) | (-18%, -12%) | (-15%, -9%) | (-17%, -11%) |
HoFH in Adults and Pediatric Patients
A trial was conducted to assess the efficacy of ZETIA in the treatment of HoFH. This double-blind, randomized, 12-week trial enrolled 50 patients (age range 11 to 74 years, 58% female; 90% White, 2% Black or African American, 8% other races identified as Hispanic or Latino) with a clinical and/or genotypic diagnosis of HoFH, with or without concomitant LDL apheresis, already receiving atorvastatin or simvastatin (40 mg). Patients were randomized to one of three treatment groups, atorvastatin or simvastatin (80 mg), ZETIA administered with atorvastatin or simvastatin (40 mg), or ZETIA administered with atorvastatin or simvastatin (80 mg). Due to decreased bioavailability of ezetimibe in patients concomitantly receiving cholestyramine [see Drug Interactions (7)], ezetimibe was dosed at least 4 hours before or after administration of resins. Mean baseline LDL-C was 341 mg/dL in those patients randomized to atorvastatin 80 mg or simvastatin 80 mg alone and 316 mg/dL in the group randomized to ZETIA plus atorvastatin 40 or 80 mg or simvastatin 40 or 80 mg. ZETIA, administered with atorvastatin or simvastatin (40- and 80-mg statin groups, pooled), significantly reduced LDL-C (21%) compared with increasing the dose of simvastatin or atorvastatin monotherapy from 40 to 80 mg (7%). In those treated with ZETIA plus 80-mg atorvastatin or with ZETIA plus 80-mg simvastatin, LDL-C was reduced by 27%.
Homozygous Sitosterolemia (Phytosterolemia) in Adults and Pediatric Patients
A trial was conducted to assess the efficacy of ZETIA in the treatment of homozygous sitosterolemia. In this multicenter, double-blind, placebo-controlled, 8-week trial, 37 patients (age range 9 to 72 years, 65% females; 89% White, 3% Asian, 8% other races identified as Hispanic or Latino) with homozygous sitosterolemia with elevated plasma sitosterol levels (>5 mg/dL) on their current therapeutic regimen (diet, bile-acid-binding resins, statins, ileal bypass surgery and/or LDL apheresis), were randomized to receive ZETIA (n=30) or placebo (n=7). Due to decreased bioavailability of ezetimibe in patients concomitantly receiving cholestyramine [see Drug Interactions (7)], ZETIA was dosed at least 2 hours before or 4 hours after resins were administered. Excluding the one subject receiving LDL apheresis, ZETIA significantly lowered plasma sitosterol and campesterol, by 21% and 24% from baseline, respectively. In contrast, patients who received placebo had increases in sitosterol and campesterol of 4% and 3% from baseline, respectively. For patients treated with ZETIA, mean plasma levels of plant sterols were reduced progressively over the course of the trial. Reductions in sitosterol and campesterol were consistent between patients taking ZETIA concomitantly with bile acid sequestrants (n=8) and patients not on concomitant bile acid sequestrant therapy (n=21).
16. How is Zetia supplied
ZETIA 10 mg tablets are white to off-white, capsule-shaped, and debossed with "414" on one side and are supplied as follows:
Package Size | NDC |
Bottle of 30 tablets | 78206-178-01 |
17. Patient Counseling Information
Advise the patient to read the FDA-Approved Patient Labeling (Patient Information).
Inform patients that ZETIA may cause liver enzyme elevations [see Warnings and Precautions (5.2)].
Muscle Pain
Advise patients that ZETIA may cause myopathy and rhabdomyolysis. Inform patients that the risk is also increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever [see Warnings and Precautions (5.3), and Drug Interactions (7)].
Pregnancy
Advise patients to inform their healthcare provider of a known or suspected pregnancy to discuss if ZETIA should be discontinued [see Use in Specific Populations (8.1)].
Breastfeeding
Advise patients who have a lipid disorder and are breastfeeding to discuss the options with their healthcare provider [see Use in Specific Populations (8.2)].
Missed Dose
Instruct patients to take ZETIA only as prescribed. If a dose is missed, it should be taken as soon as possible. Advise patients not to double their next dose.
This Patient Information has been approved by the U.S. Food and Drug Administration. | Revised: 7/2023 | ||
PATIENT INFORMATION ZETIA [zeh-TEE-uh] (ezetimibe) tablets, for oral use |
|||
Read this information carefully before you start taking ZETIA® and each time you get more ZETIA. There may be new information. This information does not take the place of talking with your doctor about your medical condition or your treatment. If you have any questions about ZETIA, ask your doctor. Only your doctor can determine if ZETIA is right for you. | |||
What is ZETIA? | |||
ZETIA is a medicine used with a cholesterol lowering diet: | |||
|
|||
ZETIA is also used: | |||
|
|||
The safety and effectiveness of ZETIA has not been established in children: | |||
|
|||
Do not take ZETIA: | |||
|
|||
Before you take ZETIA, tell your healthcare provider about all your medical conditions, including if you:
|
|||
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Talk to your healthcare provider before you start taking any new medicines. | |||
Taking ZETIA with certain other medicines may affect each other causing side effects. ZETIA may affect the way other medicines work, and other medicines may affect how ZETIA works. | |||
Especially tell your healthcare provider if you take:
|
|||
Ask your healthcare provider or pharmacist for a list of medicines if you are not sure. Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist when you get a new medicine. | |||
How should I take ZETIA?
|
|||
What are the possible side effects of ZETIA?
ZETIA may cause serious side effects including:
|
|||
Your chances of getting muscle problems are higher if you are also taking statins or fibrates. The most common side effects of ZETIA taken alone include: |
|||
|
|
|
|
The most common side effects of ZETIA taken with a statin include: | |||
|
|
|
|
Tell your healthcare provider if you have any side effect that bothers you or does not go away. | |||
These are not all the possible side effects of ZETIA. | |||
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. | |||
How should I store ZETIA?
|
|||
Keep ZETIA and all medicines out of the reach of children. | |||
General information about safe and effective use of ZETIA. | |||
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use ZETIA for a condition for which it was not prescribed. Do not give ZETIA to other people, even if they have the same symptoms you have. It may harm them. You can ask your pharmacist or healthcare provider for information about ZETIA that is written for health professionals. |
|||
What are the ingredients in ZETIA? | |||
Active ingredient: ezetimibe. | |||
Inactive ingredients: croscarmellose sodium NF, lactose monohydrate NF, magnesium stearate NF, microcrystalline cellulose NF, povidone USP, and sodium lauryl sulfate NF. | |||
Manuf. for: Organon LLC, a subsidiary of ORGANON & Co., Jersey City, NJ 07302, USA For patent information: www.organon.com/our-solutions/patent/ © 2023 Organon group of companies. All rights reserved. For more information, go to www.organon.com/our-focus/products-list/ or call 1-844-674-3200. usppi-og0653-t-2307r001 |
ZETIA
ezetimibe tablet |
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
Labeler - Organon LLC (117494753) |